Video & Transcript : 'FDA user fees' :

Page 28 of 500
MO

Missouri 2026 Regular Session

Emerging Issues Feb 25th, 2026

Emerging Issues

Transcript Highlights:
  • So the FDA has drawn this line.
  • And so our FDA... ...our FDA protected us from those kinds of side effects because they insisted on these
  • When the FDA announced in... ...to the people of Missouri, when the FDA announced in July of last year
  • The FDA, in all of its statements, is saying we're only going after 7-OH.
  • Repeatedly, the commissioner of the FDA has made that statement.
LA

Louisiana 2026 Regular Session

Senate May 26th, 2026

Louisiana Senate Floor Meeting

Transcript Highlights:
  • to provide for the calculation of oilfield site restoration fees.
  • to provide for the calculation of oilfield site restoration fees.
  • This right-sizes the community to the collection of the fee.
  • From 5,000 to 9,000, this right-sizes the community to the collection of the fee.
  • It also allows the city to recover court costs and attorney fees in that pursuit.
Bills: SR146 , SCR12 , HB221 , HCR115 , HCR116 , HCR58 , HB1 , HB312 , HB313 , HB314 , HB383 , HB983 , HB1126 , HCR3 , HB2 , HB3 , SCR3 , SB56 , SCR9 , SCR58 , SB35 , SB65 , SB215 , SB246 , SB249 , SB269 , SB282 , SB296 , SB323 , SB363 , SB369 , SB474 , SB490 , SB492 , SB500 , SB514 , HCR27 , HCR28 , HCR66 , HCR67 , HCR72 , HCR5 , HCR32 , HCR49 , HCR50 , HCR53 , HCR60 , HCR62 , HCR64 , HCR68 , HCR78 , HCR81 , HCR86 , HCR97 , HCR102 , HCR31 , HCR47 , HB476 , HB481 , HB487 , HB492 , HB549 , HB579 , HB608 , HB621 , HB624 , HB626 , HB632 , HB637 , HB656 , HB722 , HB745 , HB804 , HB818 , HB821 , HB833 , HB864 , HB867 , HB874 , HB893 , HB909 , HB951 , HB968 , HB969 , HB978 , HB979 , HB988 , HB989 , HB1001 , HB1005 , HB1007 , HB1024 , HB1032 , HB1050 , HB1051 , HB1056 , HB1059 , HB1077 , HB1080 , HB1081 , HB1086 , HB1108 , HB1112 , HB1153 , HB1172 , HB1173 , HB1175 , HB1192 , HB1193 , HB1204 , HB1218 , HB1242 , HB1244 , HB1249 , HB1252 , HB1254 , HB42 , HB45 , HB71 , HB79 , HB158 , HB160 , HB169 , HB227 , HB251 , HB289 , HB330 , HB394 , HB410 , HB429 , HB769 , HB971 , HB1017 , HB1234 , HB1235 , HB9 , HB177 , HB181 , HB202 , HB223 , HB225 , HB387 , HB398 , HB457 , HB459 , HB540 , HB591 , HB616 , HB766 , HB775 , HB783 , HB895 , HB906 , HB950 , HB975 , HB1052 , HB1057 , HB1076 , HB1100 , HB1139 , HB1155 , HB1160 , HB1182 , HB1186 , HB1220 , HB1223 , HB1224 , HB1228 , HB1231 , HB1245 , HB1256 , HB17 , HB27 , HB36 , HB41 , HB47 , HB73 , HB126 , HB133 , HB140 , HB159 , HB166 , HB205 , HB211 , HB226 , HB259 , HB271 , HB308 , HB310 , HB324 , HB337 , HB351 , HB399 , HB403 , HB571 , HB712 , HB723 , HB726 , HB740 , HB750 , HB759 , HB812 , HB844 , HB966 , HB1006 , HB1009 , HB1018 , HB1036 , HB1038 , HB1107 , SB29 , SB42 , SB78 , SB208 , SB217 , SB274 , SB300 , SB341 , SB379 , SB382 , SB387 , SB401 , SB441 , SB449 , SB487 , HB74 , HB134 , HB258 , HB359 , HB468 , HB956 , HB1117 , SB43 , SB149
LA

Louisiana 2026 Regular Session

House of Representatives Apr 22nd, 2026

Louisiana House Floor Meeting

Transcript Highlights:
  • , to establish procedures to dispute fees and charges.
  • It also provides for an increase in some of the fees charged relative to licensing fees and renewal fees
  • , maximum fee amount.
  • So this bill will increase that fee. I'm not going to pass the bill.
  • The law requires app stores to verify the age of users.
HI

Hawaii 2026 Regular Session

CPC Public Hearing - Thu Apr 9, 2026 @ 2:00 PM HST

Consumer Protection & Commerce

Transcript Highlights:
  • /c><01:02:13.840><c> of</c> approved by the FDA as the FDA kind of approved by the FDA as the FDA kind
  • And you know, at AAFCO by AAFCO and FDA.
  • </c> be fine with it as long as it's FDA be fine with it as long as it's FDA approved.<01:06:09.040><
  • </c><01:07:52.400><c> Oh</c> other agencies you know, maybe FDA Oh other agencies you know, maybe FDA
  • </c> mechanism for maritime fee changes. mechanism for maritime fee changes.
Summary: The committee on Consumer Protection and Commerce met on April 9, 2026, and heard testimony on several measures. SB 3302 SD1 HD1, dealing with homemade food products, would require the Department of Health to adopt rules for farm kitchens producing homemade food products that are no more stringent than rules for home kitchens. The Department of Health said it supported the bill with technical amendments, and the Hawaii Food Industry Association and Grassroot Institute of Hawaii also supported it. No opposition was heard. A lengthy discussion focused on SB 2061 SD2 HD1, which concerns a 99-year leasehold residential condominium project and HCDA’s rules for sales, income restrictions, and buyback pricing. HCDA supported the bill and said the House draft clarified unclear provisions and would help move the project to pre-sales. Testimony and committee questions centered on whether the project should remain owner-occupied in perpetuity or allow investor purchases after an initial sales period. HCDA explained that the bill was revised to make the project feasible in the market, that 60% of units would be income-restricted for buyers at or below 140% of area median income, and that the remaining units could be sold without owner-occupancy restrictions. Some members and testifiers expressed concern that the bill had shifted away from the original owner-occupancy vision and could become an investment property model, while others argued the changes were necessary for the project to pencil out and compete with fee-simple developments. No vote was taken during the discussion shown. The committee also heard SB 2050 SD1 HD1, which would allow chiropractic students in accredited programs to engage in clinical practice beginning July 1, 2028. The Hawaii Board of Chiropractic and the Hawaii State Chiropractic Association supported the measure, and one testifier described personal experience with student chiropractic care in California. Members questioned why the board requested delaying implementation until 2030, and the board said it needed more time to develop rules because it meets only a few times a year and rulemaking is lengthy. Finally, SB 2102 SD2 HD1, on industrial hemp in commercial feed, was introduced; the Department of Agriculture and Biosecurity offered comments, the Department of Health raised concerns about regulating pet food and possible jurisdictional conflict, and a farmer testifying in support suggested narrowing the bill to federally approved livestock feed rather than pet food.
KY
Transcript Highlights:
  • </c><00:05:50.720><c> between</c> these were approved by the FDA between these were approved by the FDA
  • </c> it breaks down between uh MCO and um fee it breaks down between uh MCO and um fee for<00:09:12.160
  • </c> A small number are used for other FDA A small number are used for other FDA approved<00:10:22.720
  • ><c> per</c> The average dispensing fee per The average dispensing fee per prescription<00:14:44.320>
  • </c> preparations were approved by the FDA preparations were approved by the FDA for<00:19:14.320><c>
Summary: The Medicaid Oversight and Advisory Board met on February 23, 2026, approved the January 12 minutes, and then focused primarily on Kentucky Medicaid’s coverage and potential expansion of GLP-1 drugs, especially for weight loss. Department for Medicaid Services Commissioner Lisa Lee explained that Medicaid currently does not cover drugs for weight loss, anorexia, or weight gain, but the department had filed a regulation to remove that blanket exclusion so GLP-1s could be covered when used for an underlying health condition. She said the administrative regulation review subcommittee found the regulation deficient, and the co-chairs wanted the board to discuss the policy and financing implications before any change. DMS also said it would be open to adding caveats to ensure coverage would not extend to cosmetic weight loss alone. The department provided several data points on current utilization and spending. In 2025, Kentucky Medicaid paid for appetite-stimulating drugs such as Megestrol, Dronabinol, and Marinol, but did not pay for weight-loss drugs. For GLP-1s, DMS said coverage began in 2025 and is limited to FDA-approved medical conditions, with prior authorization requiring a type 2 diabetes diagnosis code and A1C documentation. DMS reported $234.6 million in GLP-1 spending in 2025 before rebates, about 240,931 prescriptions, and said GLP-1s accounted for 7.3% of pharmacy spend in 2024 and 8.3% in 2025. It also said there were 24,844 expansion members and 13,638 non-expansion members using GLP-1s, with spending of about $156 million and $78.5 million respectively, and that 10 pediatric weight-loss prescriptions were covered under EPSDT. The department said outcome analyses, including whether GLP-1 use reduces insulin or other diabetes treatment, are underway and should be completed in a couple of months. Members asked about cost, rebates, and whether the state should wait for more outcomes data before expanding coverage. DMS said average reimbursement to pharmacies was $975 per prescription and the average dispensing fee was $109; it also said 2025 rebate invoices totaled $90.8 million, with $7.6 million collected so far. Several members expressed concern about the high cost and the need to evaluate whether the drugs improve health outcomes before expanding access, while others noted the potential benefits for obesity and diabetes treatment. Some members also discussed whether GLP-1s are effectively being used for weight loss in diabetic patients and whether broader data collection should be used to assess long-term value. After the Medicaid discussion, Eli Lilly executive Tracy Sims presented on obesity as a chronic disease and the economic burden it creates in Kentucky. She said Kentucky’s adult obesity rate is a little over 37%, that obesity is linked to about 200 diseases, and that untreated obesity costs the state billions in GDP and hundreds of millions in state budget impact. She highlighted recent federal access programs for GLP-1s, including a Medicaid-related program that she said could lower the state share of a Zepbound prescription to about $71 per month after federal matching. No votes were taken on the GLP-1 policy question during the meeting, and the main action was the receipt of testimony and discussion of the department’s proposed regulatory change.
VT

Vermont 2025-2026 Regular Session

Senate Session - 2026-05-05 - 9:30AM

Vermont Senate Floor Meeting

Transcript Highlights:
  • </c> convenience fee? convenience fee?
  • </c> established by the FDA. established by the FDA.
  • FDA. FDA.
  • </c> established by the US FDA. established by the US FDA.
  • So, um in fact, the FDA<01:57:49.640><c> has</c><01:57:50.640><c> um</c> FDA has um FDA has um they<01
MA

Massachusetts 2025-2026 Regular Session

Joint Committee on Public Health Jun 21st, 2026 at 10:00 am

Joint Committee on Public Health

Transcript Highlights:
  • Health care is in fact one of the biggest users of single-use plastic in our country.
  • When you add in credit card fees on many of these other transactions, the cost isn't just financial.
  • There are wide variances between municipalities in permitting fees, expiration dates, and protocols,
  • The fees range from $50 to $300.
  • The FDA has realistically already done the heavy lifting for all states.
Summary: The Joint Committee on Public Health held a lengthy hearing to take testimony on a wide range of bills related to environmental health, PFAS, medical device chemicals, food access, lead poisoning, air quality, oral health, and school food additives. Chair Driscoll and Chair Decker emphasized that the hearing was for testimony only, no decisions would be made that day, and that written testimony could still be submitted. They also noted the high volume of speakers and asked witnesses to keep remarks brief. A major portion of the hearing focused on PFAS-related legislation, including bills to restrict PFAS in products and food packaging and to create a PFAS remediation trust fund. Municipal officials and advocates described the high costs of PFAS cleanup, especially for drinking water systems, citing Easton’s multimillion-dollar treatment investments and rate increases. Testimony from legislators and advocates argued that Massachusetts should act despite federal uncertainty, and that the state should stop PFAS at the source rather than leaving municipalities and residents to pay for remediation. The committee also heard strong support for a bill banning DEHP in medical devices, with physicians, nurses, and a bill sponsor saying the chemical can leach from IV bags and tubing and that safer alternatives already exist. The committee also heard testimony on bills to establish statewide food truck permitting, with food truck owners and a senator describing the current system as costly, duplicative, and inconsistent across municipalities. Another set of witnesses supported the “Bean New Deal,” which would expand plant-based food options in public institutions, senior nutrition programs, and WIC, citing health, equity, and cost savings. On lead poisoning, housing advocates and a representative backed bills to expand lead-safe housing requirements to all rental units, arguing the current law contributes to discrimination against families with children and leaves too much pre-1978 housing uncertified. The committee also heard support for an outdoor air pollution bill that would create an advisory committee, identify pollution hotspots, expand monitoring, and set reduction targets, with testimony from environmental justice groups, pediatricians, and legislators describing disproportionate asthma and other health harms in overburdened communities. Later testimony addressed oral health bills to create dental therapists and allow dental hygienists to administer nitrous oxide, with supporters saying the measures would expand access, reduce costs, and help underserved patients. The committee also heard testimony on a bill to prohibit harmful food dyes in competitive school foods, with parents describing behavioral and health concerns tied to synthetic dyes. No votes or formal actions were taken during the hearing.
CA
Transcript Highlights:
  • Users to create non-consensual content featuring anyone.
  • It should reduce fines, fees, and insurance burdens.
  • SABA advocates for safe streets for all users.
  • It holds users legally responsible even if they didn't know that the software misused data.
  • The number of potential violations that a user can be subject to has been limited.
Summary: The committee heard several AI- and consumer-protection-related bills, with extensive testimony from authors, supporters, and industry opponents. SB 53 by Senator Wiener would create transparency requirements for large AI developers, including disclosure of safety and security protocols, reporting of critical safety incidents, whistleblower protections, and the CalCompute public cloud. Supporters said it is a narrower, transparency-based follow-up to last year’s vetoed AI safety bill, while opponents argued it still relies too much on company size, could expose trade secrets, and should be narrowed further. The committee approved SB 53 on a do-pass-as-amended vote to Appropriations, with the roll held open for absent members. SB 766 by Senator Allen would codify the FTC’s Cars Rule and create a three-day cooling-off period for certain used-car purchases, along with stronger disclosure rules on pricing, add-ons, and government affiliation claims. Supporters said it would save consumers money and time and help buyers avoid bad deals, while dealer and industry groups said amendments addressed many of their concerns. Several former opponents moved to neutral, and the committee passed SB 766 unanimously as amended to Appropriations. SB 7 by Senator McNerney would regulate automated decision-making systems in employment by requiring notice, human review for discipline and termination, and limits on predictive behavior analysis. Labor and consumer advocates supported the bill as a safeguard against biased or overly automated workplace decisions, while employer and industry groups raised concerns about scope, notice burdens, and the predictive-analysis ban. The committee passed SB 7 to Appropriations on a 4-2 vote, with the roll held open. SB 833, also by Senator McNerney, would require human oversight of AI used in critical infrastructure, along with training and system assessments; it drew limited opposition focused on scope, and the committee passed it as amended to Appropriations on a 5-0 vote, also holding the roll open. Later, the committee took up SB 11, which would address AI-generated voice, image, and video cloning and deepfakes by clarifying likeness protections, requiring consumer warnings, and addressing misuse and evidence tampering. Supporters framed it as a targeted response to nonconsensual deepfakes, while industry groups said recent amendments improved the bill but still had concerns about penalties and warning language. The committee also heard SB 720, the Safer Streets Act, which would let cities opt into a revised red-light camera system that shifts from driver to owner liability, removes facial identification, makes violations civil rather than criminal, and directs revenue toward transportation safety projects; the author presented the bill, but the transcript ends before any final action on SB 720.
MO

Missouri 2026 Regular Session

Emerging Issues Feb 25th, 2026

Emerging Issues and Professional Registration

Transcript Highlights:
  • So the FDA has drawn this line.
  • And so our FDA... ...and hundreds of babies.
  • I am an FDA regulatory attorney, and I previously served.
  • The FDA, in all of its statements, is saying we're only going after 7-OH.
  • Repeatedly, the commissioner of the FDA has made that statement.
Summary: The committee first met in executive session and adopted House Committee Substitutes, then passed several bills by roll call vote. HCS for House Bills 1746 and 1769 was adopted and then voted do pass by 10-0. HCS for House Bill 3005 was adopted and passed 10-0 after the sponsor explained it removed a sentence requiring specific local review boards in library appeals processes. HCS for House Bills 1717 and 1643, dealing with alternative therapies, passed 7-2 with two present. HCS for House Bills 2817 and 2961 passed 8-1 with two present. HCS for House Bills 2035 and 2350 passed 10-0 with one present after a brief question about statutory citations. HCS for House Bills 1887, 2361, 1913, 2862, and 2321, a combined bill package, also passed 10-0 after members discussed digital depiction language and written victim request provisions. The committee then held a public hearing on House Bill 1914, which would change Missouri’s franchise law on warranty and recall reimbursement for auto dealers. Rep. David Castile presented the bill as a fairness measure, arguing manufacturers should pay dealers market-rate labor and parts reimbursement and that current warranty work often loses money for dealers and hurts service access. Supporters, including several dealers and technicians, said manufacturer time guides underpay warranty work, that the bill would help retain technicians, and that current appeal processes are cumbersome and time-consuming. They described large gaps between warranty and customer-pay labor times and said technicians often invest heavily in tools and training. Opponents, including the Alliance for Automotive Innovation, Toyota, General Motors, Ford, and business groups, argued the bill would raise costs for consumers, amount to a large increase in dealer compensation, and interfere with existing contracts. They said manufacturers already provide a process for requesting additional time, that most requests are approved, and that warranty work remains a profitable captive source of business for dealers. Several witnesses also argued the bill would not directly raise technician wages because technicians are employed by dealers, not manufacturers, and suggested broader competition or allowing independent repair shops instead. The hearing featured extensive questioning about recall versus warranty work, labor time guides, documentation requirements, and whether the legislature should be involved in these franchise disputes.
LA

Louisiana 2026 Regular Session

Transportation, Highways and Public Works May 21st, 2026

Transportation, Highways & Public Works

Transcript Highlights:
  • What kind of fees are they putting on it? Currently, we refer to Office of Debt Recovery.
  • I don't know what the Attorney General's fees are.
  • Reinstatement fees up to 30 days, $75; 31 to 90 days, $150; over 90 days, $300.
  • So these are insurance lapse reinstatement fees.
  • They have to pay collection fees and 15% from ODR.
Bills: HCR32 , HCR53 , HCR60 , HCR68 , HB582 , HB730 , HB762
LA

Louisiana 2026 Regular Session

Appropriations Apr 22nd, 2026

Appropriations

Transcript Highlights:
  • Fees in there. Pretty sneaky. All right. I see no hidden fees.
  • It's a $2 fee for each renewal, which is about 50 cents a year.
  • And this small fee does that. And I agree with what you said.
  • I got to pay $60 for my hybrid fee this month.
  • We keep adding money to the driver's license fee.
Bills: HB316 , HB549 , HB646 , HB752 , HB824 , HB873 , HB1129 , HB1157 , HB1170
MN

Minnesota 2025-2026 Regular Session

House Higher Education Finance and Policy Committee 4/16/26

Higher Education Finance and Policy

Transcript Highlights:
  • So this revises that cap and sets it at either the lesser of the average tuition and fees charged by
  • Um, above tuition, above fees, above room and board, above all of those things.
  • ,</c><01:08:47.120><c> your</c> or less, your tuition, your fees, your or less, your tuition, your fees
  • They will only be covered by the North Star Promise, which only covers the tuition and fees.
  • </c><01:29:34.320><c> at</c><01:29:34.560><c> a</c> tuition and fees at a tuition and fees at a public
Bills: HF4252
MN

Minnesota 2025-2026 Regular Session

House Commerce Finance and Policy Committee 4/9/26

Commerce Finance and Policy

Transcript Highlights:
  • Surrogacy costs vary, but after compensation, agency fees, IVF embryo creation and transfer, legal fees
  • ><c> legal</c><00:21:50.720><c> fees,</c><00:21:50.960><c> and</c> creation and transfer, legal fees,
  • These platforms make money by charging a bettor a fee, bringing together users and the opposite side
  • They pay zero in state taxes, zero in regulatory fees.
  • And that means the regulatory fees.
Bills: HF1758 , HF4437 , HF4353
LA

Louisiana 2026 Regular Session

Administration of Criminal Justice Apr 8th, 2026

Administration of Criminal Justice

Transcript Highlights:
  • It prohibits the assessment of any fees or costs against certain individuals who request a copy of testimony
  • if a victim or family member of a victim requests a copy of the transcript, they can't be assessed a fee
Bills: HCR7 , HB76 , HB84 , HB132 , HB265 , HB275 , HB322 , HB635 , HB808 , HB883 , HB1054
WA

Washington 2025-2026 Regular Session

House Local Government Jan 16th, 2026 at 10:30 am

Local Government

Transcript Highlights:
  • its final decision by a deadline, then it may be required to refund either 10 or 20% of the permit fee
  • in review by a local government during any period in which an applicant has not paid an applicable fee
  • in review by a local government during any period in which an applicant has not paid an applicable fee
  • If an entity misses its review deadline, it would need to refund 20% of the fee that it collected.
  • We currently have jurisdictions telling us we must pay permit fees, yet they won't give us the fees for
Bills: HB2228 , HB2273 , HB2418 , HB2381
AL

Alabama 2026 Regular Session

Alabama House State Government Committee Jan 14th, 2026

State Government

Transcript Highlights:
  • Um, it's going to change the licensing fees where right now water well contractor license with the state
  • Thirdly, the bill requires app stores to verify whether a user is an adult or a minor, and that is key
  • requires app stores to verify<00:13:34.800><c> whether</c><00:13:35.120><c> a</c><00:13:35.360><c> user
  • is an adult or a verify whether a user is an adult or a minor<00:13:37.040><c> and</c><00:13:37.279>
  • She said this allows developers like Meta to place younger users into age-appropriate experiences on
Bills: HB69 , HB114 , HB161 , HB69 , HB114 , HB161
TX

Texas 89th Regular

S/C on Family & Fiduciary Relationships May 5th, 2025

S/C on Family & Fiduciary Relationships

Transcript Highlights:
  • There's a $45 fee.
  • What Zaffirini has done is to say the fee ought to be the same, it's not any different from taking a
  • State of Texas, family law case is a $45 transfer fee. It shouldn't be any difference to go from.
  • California to here to Travis to have that $45 fee are from El Paso to Travis County for $45 fee and that's
  • That's for a fee. Thank you, Judge Herman. Any questions of Judge Herman, members?
AL

Alabama 2025 Regular Session

Alabama Senate Healthcare Committee Mar 19th, 2025

Healthcare

Transcript Highlights:
  • In a recent 13-month period, the FDA and the National Poison Control have seen an uptick in...
  • Yeah, so we first have to apply for a license, pay your fee, and after you get your license, you're allowed
  • I'd also like to make the point that the only FDA-approved cannabis product is Marinol and... ...approved
  • The FDA says synthesized THC is good, so they approved it. And that's Marinol.
Bills: HB194 , SB87 , SB237
Committee: Senate Healthcare
FL

Florida 2026 Regular Session

Health Policy Feb 11th, 2026

Health Policy

Transcript Highlights:
  • The cellular-type therapy, I guess, we're doing, is not FDA approved.
  • And Senator Davis, no, they're not FDA-approved uses, but they are being used off-label.
  • That is one of the core functions of the bill, other than the veteran fee waiver.
  • All the blue is their profit that they kept after expenses and after admin fees.
  • All the blue is their profit that they kept after expenses and after admin fees.
Bills: S0688 , S1414 , S0186 , S0902 , S0196 , S1574 , S0878 , S1092 , S1032 , S1684 , S1686 , S1760